Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 4/2018

15.08.2018 | Neurogenic Bladder (C Powell, Section Editor)

Contemporary Treatment of Detrusor Sphincter Dyssynergia: a Systematic Review

verfasst von: Hanhan Li, Nickolas Nahm, Alex Borchert, Philip Wong, Humphrey Atiemo

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To systematically review the literature to determine outcomes of detrusor sphincter dyssynergia (DSD) treatments. DSD can present in patients with neurogenic bladder due to a variety of conditions, but no treatment guidelines currently exist. Ovid Medline, Embase, PubMed, and Web of Science were searched within the last 10 years for “detrusor sphincter dyssynergia.” Results were independently reviewed by two coauthors for inclusion using the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA) guidelines. Exclusion criteria were pediatric populations, reviews, non-clinical focus, non-English language, and case reports.

Recent Findings

There were 515 articles screened to yield 21 full text articles. Fourteen were retrospective studies, five were prospective non-randomized studies, and two were prospective, randomized trials. A total of 830 patients (527 male, 104 female, and 199 not specified) had DSD from spinal cord injury (413), multiple sclerosis (104), multiple system atrophy (33), and not specified (280). Treatments included botulinum A injections into the external sphincter (seven studies, reported success rates = 64–100%) or bladder (three studies, 44–76%), urethral stents (four studies, 9–91%), sphincterotomy (two studies, 48–85%), transurethral incision of the bladder neck (one study, 82%), pharmacologic therapy (three studies, 44–76%), sacral neuromodulation (one study, 60%), and anal stretch (one study).

Summary

Evaluation of treatment outcomes for DSD is lacking. If conservative therapy fails, botulinum toxin type A injection appears to be a primary intervention strategy. More invasive treatments such as sacral neuromodulation and transurethral incision of the bladder neck also demonstrated high success rates, while urethral stenting was associated with high complication and failure rates.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Blaivas JG, Sinha HP, Zayed AA, Labib KB. Detrusor-external sphincter dyssynergia: a detailed electromyographic study. J Urol. 1981;125(4):545–8.PubMedCrossRef
2.
Andersen JT, Bradley WE. The syndrome of detrusor-sphincter dyssynergia. J Urol. 1976;116(4):493–5.PubMedCrossRef
3.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.PubMedCrossRef
4.
Blaivas JG. The neurophysiology of micturition: a clinical study of 550 patients. J Urol. 1982;127(5):958–63.PubMedCrossRef
5.
Blaivas JG, Barbalias GA. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol. 1984;131(1):91–4.PubMedCrossRef
6.
Blaivas JG, Sinha HP, Zayed AA, Labib KB. Detrusor-external sphincter dyssynergia. J Urol. 1981;125(4):542–4.PubMedCrossRef
7.
Kirby R, Fowler C, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry. 1986;49(5):554–62.PubMedPubMedCentralCrossRef
8.
Bacsu CD, Chan L, Tse V. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int. 2012;109(Suppl 3):31–4.PubMedCrossRef
9.
Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol. 1992;147(2):416–8.PubMedCrossRef
10.
11.
Ahmed HU, Shergill IS, Arya M, Shah PJ. Management of detrusor-external sphincter dyssynergia. Nat Clin Pract Urol. 2006;3(7):368–80.PubMedCrossRef
12.
Dmochowski RR, Ganabathi K, Leach GE. Non-operative management of the urinary tract in spinal cord injury. Neurourol Urodyn. 1995;14(1):47–55.PubMedCrossRef
13.
Kim YH, Bird ET, Priebe M, Boone TB. The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol. 1997;158(6):2083–6.PubMedCrossRef
14.
Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol. 2001;19(5):299–306.PubMedCrossRef
15.
Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992;239(1):16–20.PubMedCrossRef
16.
Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRef
17.
Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–9.PubMedCrossRef
18.
Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.PubMedCrossRef
19.
Ross JC, Damanski M, Gibbon N. Resection of the external urethral sphincter in the paraplegic; preliminary report. J Urol. 1958;79(4):742–6.PubMedCrossRef
20.
Hamid R, Arya M, Patel HR, Shah PJ. The mesh wallstent in the treatment of detrusor external sphincter dyssynergia in men with spinal cord injury: a 12-year follow-up. BJU Int. 2003;91(1):51–3.PubMedCrossRef
21.
Catz A, Luttwak ZP, Agranov E, Ronen J, Shpaser R, Paz A, et al. The role of external sphincterotomy for patients with a spinal cord lesion. Spinal Cord. 1997;35(1):48–52.PubMedCrossRef
22.
Milroy EJ, Chapple CR, Cooper JE, Eldin A, Wallsten H, Seddon AM, et al. A new treatment for urethral strictures. Lancet. 1988;1(8600):1424–7.PubMedCrossRef
23.
Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: lessons learned. J Urol. 2002;167(6):2477–80.PubMedCrossRef
24.
Soni BM, Vaidyanatham S, Krishnan KR. Use of Memokath, a second generation urethral stent for relief of urinary retention in male spinal cord injured patients. Paraplegia. 1994;32(7):480–8.PubMed
25.
Weld KJ, Wall BM, Mangold TA, Steere EL, Dmochowski RR. Influences on renal function in chronic spinal cord injured patients. J Urol. 2000;164(5):1490–3.PubMedCrossRef
26.
Yalla SV, Blunt KJ, Fam BA, Constantinople NL, Gittes RF. Detrusor-urethral sphincter dyssynergia. J Urol. 1977;118(6):1026–9.PubMedCrossRef
27.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.CrossRef
28.
Huang YH, Chen SL, Tsai SJ, Bih LI, Lew HL. Urodynamic responses to anal stretch in patients with detrusor sphincter dyssynergia. Arch Phys Med Rehabil. 2008;89(9):1748–52.PubMedCrossRef
29.
Ito T, Sakakibara R, Yasuda K, Yamamoto T, Uchiyama T, Liu Z, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord. 2006;21(6):816–23.PubMedCrossRef
30.
Kilicarslan H, Ayan S, Vuruskan H, Gokce G, Gultekin EY. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol. 2006;38(3–4):537–41.PubMed
31.
Nardulli R, Losavio E, Ranieri M, Fiore P, Megna G, Bellomo RG, et al. Combined antimuscarinics for treatment of neurogenic overactive bladder. Int J Immunopathol Pharmacol. 2012;25(1 Suppl):35S–41S.PubMedCrossRef
32.
Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin A injection. Urology. 2008;72(5):1056–60.PubMedCrossRef
33.
Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord. 2011;49(5):659–64.PubMedCrossRef
34.
Kuo HC. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. Int J Clin Pract. 2013;67(10):1044–9.PubMedCrossRef
35.
Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670–6.PubMedPubMedCentralCrossRef
36.
Liao YM, Kuo HC. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology. 2007;70(4):763–6.PubMedCrossRef
37.
Chen SL, Bih LI, Huang YH, Tsai SJ, Lin TB, Kao YL. Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J Rehabil Med. 2008;40(9):744–8.PubMedCrossRef
38.
Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009;90(5):832–6.PubMedCrossRef
39.
Chen SL, Bih LI, Chen GD, Huang YH, You YH. Comparing a transrectal ultrasound-guided with a cystoscopy-guided botulinum toxin a injection in treating detrusor external sphincter dyssynergia in spinal cord injury. Am J Phys Med Rehabil. 2011;90(9):723–30.PubMedCrossRef
40.
• Yang WX, Zhu HJ, Chen WG, Zhang DW, Su M, Feng JF, et al. Treatment of detrusor external sphincter dyssynergia using ultrasound-guided trocar catheter transurethral botulinum toxin a injection in men with spinal cord injury. Arch Phys Med Rehabil. 2015;96(4):614–9. This recent paper describes using botox treatment for DSD in patients with spinal cord injury. PubMedCrossRef
41.
Mehta SS, Tophill PR. Memokath stents for the treatment of detrusor sphincter dyssynergia (DSD) in men with spinal cord injury: the Princess Royal Spinal Injuries Unit 10-year experience. Spinal Cord. 2006;44(1):1–6.PubMedCrossRef
42.
Seoane-Rodriguez S, Sanchez RLJ, Montoto-Marques A, Salvador-de la Barrera S, Ferreiro-Velasco ME, Alvarez-Castelo L, et al. Long-term follow-up study of intraurethral stents in spinal cord injured patients with detrusor-sphincter dyssynergia. Spinal Cord. 2007;45(9):621–6.PubMedCrossRef
43.
Game X, Chartier-Kastler E, Ayoub N, Even-Schneider A, Richard F, Denys P. Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent. Spinal Cord. 2008;46(1):74–7.PubMedCrossRef
44.
Abdul-Rahman A, Ismail S, Hamid R, Shah J. A 20-year follow-up of the mesh wallstent in the treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury. BJU Int. 2010;106(10):1510–3.PubMedCrossRef
45.
Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol. 2012;30(1):123–8.PubMedCrossRef
46.
Pan D, Troy A, Rogerson J, Bolton D, Brown D, Lawrentschuk N. Long-term outcomes of external sphincterotomy in a spinal injured population. J Urol. 2009;181(2):705–9.PubMedCrossRef
47.
Pannek J, Hilfiker R, Goecking K, Bersch U. Preoperative urodynamic assessment in patients with spinal cord lesions undergoing sphincterotomy: is success predictable? Urol Int. 2009;83(4):386–91.PubMedCrossRef
48.
Ke QS, Kuo HC. Transurethral incision of the bladder neck to treat bladder neck dysfunction and voiding dysfunction in patients with high-level spinal cord injuries. Neurourol Urodyn. 2010;29(5):748–52.PubMedCrossRef
49.
Lindehall B, Abrahamsson K, Hjalmas K, Jodal U, Olsson I, Sillen U. Complications of clean intermittent catheterization in boys and young males with neurogenic bladder dysfunction. J Urol. 2004;172(4 Pt 2):1686–8.PubMedCrossRef
50.
Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord. 2002;40(10):536–41.PubMedCrossRef
51.
Hollingsworth JM, Rogers MA, Krein SL, Hickner A, Kuhn L, Cheng A, et al. Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. Ann Intern Med. 2013;159(6):401–10.PubMedCrossRef
52.
de Seze M, Petit H, Gallien P, de Seze MP, Joseph PA, Mazaux JM, et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56–62.PubMedCrossRef
53.
Chancellor MB, Gajewski J, Ackman CF, Appell RA, Bennett J, Binard J, et al. Long-term follow-up of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia. J Urol. 1999;161(5):1545–50.PubMedCrossRef
54.
Fontaine E, Hajri M, Rhein F, Fakacs C, Le Mouel MA, Beurton D. Reappraisal of endoscopic sphincterotomy for post-traumatic neurogenic bladder: a prospective study. J Urol. 1996;155(1):277–80.PubMedCrossRef
55.
•• Stoffel JT. Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5(1):127–35. This is a recent review of the physiology and diagnosis of DSD. This manuscript describes adjuncts to urodynamics to diagnosing DSD. PubMedPubMedCentral
56.
• Leitner L, Walter M, Sammer U, Knupfer SC, Mehnert U, Kessler TM. Urodynamic investigation: a valid tool to define normal lower urinary tract function? PLoS One. 2016;11(10):e0163847. This paper highlights the difficulty in diagnosing DSD with urodynamics as a proportion of healthy subjects were shown to have DSD by urodynamics. PubMedPubMedCentralCrossRef
57.
Barbalias GA, Nikiforidis G, Liatsikos EN. Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives. J Urol. 1998;160(1):106–11.PubMedCrossRef
58.
Wanner MB, Rageth CJ, Zach GA. Pregnancy and autonomic hyperreflexia in patients with spinal cord lesions. Paraplegia. 1987;25(6):482–90.PubMed
Metadaten
Titel
Contemporary Treatment of Detrusor Sphincter Dyssynergia: a Systematic Review
verfasst von
Hanhan Li
Nickolas Nahm
Alex Borchert
Philip Wong
Humphrey Atiemo
Publikationsdatum
15.08.2018
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2018
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-018-0482-3

Weitere Artikel der Ausgabe 4/2018

Current Bladder Dysfunction Reports 4/2018 Zur Ausgabe

Neurogenic Bladder (Charles Powell, S. Editor)

Prevalence and Cost of Catheters to Manage Neurogenic Bladder

Neurogenic Bladder (C Powell, Section Editor)

A Review of Multiple Sclerosis for Urologists and Urogynecologists with an Emphasis on Management

Neurogenic Bladder (C Powell, Section Editor)

Challenges of Training General Surgery Residents to Do Urology in the Developing World

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Shared Pathophysiology of Detrusor Overactivity and Detrusor Underactivity

Reconstructed Bladder Function and Dysfunction (M Kaufman, Section Editor)

Tibial Nerve and Sacral Neuromodulation in the Elderly Patient

Stress Incontinence and Prolapse (S Reynolds, Section Editor)

So the First Pelvic Organ Prolapse Repair Failed…Now What?

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise